Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Vital Therapies Inc (NASDAQ: VTL) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Vital Therapies Inc (NASDAQ: VTL) concerning whether a series of statements by Vital Therapies Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On July 14, 2015, Seeking Alpha released a report that alleged that Vital Therapies Inc’s representations regarding the 90 day overall survival rate for those treated with the Company’s Extracorporeal Liver Assist Device (“ELAD”) were highly misleading. The reasoning behind this allegation was that they included survival data from a patient who received a liver transplant, while no equivalent patient in the control group had received a transplant. The report claims that this fact was not disclosed in any of the Company’s prior disclosures concerning the Phase 2 VTI-206 study of ELAD.  After the release of this publication, NASDAQ: VTL shares declined approximately 16%, representing a loss of value of roughly $85 million on July 15, 2015.   

Based in San Diego, CA and founded in 2003, Vital Therapies Inc a biotherapeutic company focused on developing a cell-based therapy for the treatment of acute liver failure in the United States. The company was formerly known as Vitagen Acquisition Corp  and changed its name to Vital Therapies Inc in June 2003.

If you purchased shares of Vital Therapies Inc (NASDAQ: VTL) on or before July 14, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185